News
Probe Scientific strengthens Board with new appointment
6 December 2007
Probe Scientific has strengthened its board by the appointment of George Zajicek as a non executive director.
The Bedford-based company, who recently announced the first commercial sale and regulatory approval for the first of its product family, the continuous blood sampling device MicroEye®, are currently raising funds for the next stages of commercial development.
“Strengthening the board is an important part of our strategy” says Neil Smith, Chief Executive of Probe Scientific. “George has a tremendous reputation and has been recommended to us by a number of leading industry and financial experts”.
Probe Scientific has created MicroEye® by achieving a breakthrough in micro-separation technology that enables the blood of a critically ill patient to be monitored safely, continuously, completely automatically and in real time.
GEORGE T ZAJICEK B.Pharm., MRPharmS, FTOPRA
George is a pharmacist who started his industrial career in pharmaceuticals with Merck, Sharp and Dohme, moving to Boehringer Ingelheim where he headed up the Regulatory Group and was involved in new business development. He also spent some years with the Unilever subsidiary Unipath as Head of Product Control, where he helped to launch a new approach to pregnancy testing with the ground-breaking Clearblue pregnancy test and pioneered work targeting radioisotope-labelled monoclonal antibodies against certain cancers (now commercialised via Antisoma). His current position is Business Development Director with Axis-Shield plc, having previously been Marketing Director of Shield Diagnostics, where he played an important part in the company’s significant sales growth and its flotation on the LSE. He is the founding Chairman of BIVDA, the trade association for the UK In Vitro Diagnostics industry, and the current Chairman of DDS, a clinical trial research organisation based at Ninewells Hospital, Dundee.